RVTY

SEC Filing Summary: PerkinElmer, Inc. (10-Q)

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for PerkinElmer, Inc. (Note: The input metadata lists "REVVITY, INC.", but the filing text explicitly identifies the registrant as PerkinElmer, Inc.). The report covers the quarterly and six-month periods ended July 2, 2006. PerkinElmer operates in two primary segments: Life and Analytical Sciences (drug discovery, genetic screening, environmental analysis) and Optoelectronics (digital imaging, sensors, specialty lighting).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 2% ($9.0 million) in the quarter and 1% ($6.3 million) for the six months compared to the prior year. Growth was driven by acquisitions ($1.6 million in Q2; $3.0 million YTD) and organic growth in Life and Analytical Sciences, partially offset by unfavorable foreign exchange rates (approx. $8.5 million impact YTD).
• Profitability: Operating income from continuing operations rose significantly, up 65% in the quarter ($35.7M vs $21.7M) and 28% YTD ($64.7M vs $50.4M). This improvement was largely due to a reduction in restructuring charges (from $14.2M in Q2 2005 to a net reversal of $0.3M in Q2 2006) and lower interest expenses.
• Discontinued Operations: The company recognized a net loss of $1.3 million in discontinued operations for the quarter, compared to a net loss of $1.7 million in the prior year quarter. This includes losses on the finalization of the Fluid Sciences divestiture and a gain on the sale of the Semiconductor business ($3.7M pre-tax gain YTD).
• Stock-Based Compensation: The adoption of SFAS No. 123(R) in Q1 2006 resulted in incremental stock-based compensation expense of $2.1 million for the quarter and $3.8 million YTD.

Guidance, Outlook, and Risks

• Acquisitions: The company completed three acquisitions in the first half of 2006 (Agilix, Spectral Genomics, and C&A) totaling approximately $33 million in cash consideration. Subsequent to the quarter, it acquired J.N. Macri Technologies and NTD Laboratories for $56.65 million.
• Restructuring: A new restructuring plan (Q2 2006 Plan) was initiated to shift resources to growth product lines, incurring a $0.8 million charge. The company expects all payments for current restructuring plans to be completed by the end of 2006.
• Capital Allocation: The company repurchased 5.0 million shares of common stock for $116.4 million during the first six months of 2006. Approximately 1.7 million shares remain authorized for repurchase under the current program.
• Legal Contingencies: Significant ongoing litigation includes patent disputes with Enzo Biochem and Amersham Biosciences. While the company won a ruling in the UK case against Amersham, appeals and other proceedings (NJ and MA cases) remain pending. The company believes it has meritorious defenses but cannot estimate potential losses.
• Market Risks: Approximately 60% of business is conducted outside the U.S., exposing the company to foreign currency exchange risk. The company uses forward contracts to hedge these exposures.

Investor Verification Checklist

• Discontinued Operations Impact: Verify the final net working capital adjustments and tax implications related to the divestiture of the Fluid Sciences segment (Aerospace, Fluid Testing, Semiconductor).
• Restructuring Accruals: Confirm the remaining liability for the Q4 2005 and Q2 2006 restructuring plans and the timing of expected cash outflows.
• Legal Exposure: Monitor the status of the Amersham patent litigation (specifically the NJ and MA cases) and the Enzo Biochem dispute, as outcomes could materially affect future earnings.
• Foreign Exchange Sensitivity: Assess the impact of the strengthening U.S. dollar on future revenue, given that 60% of sales are international.
• Stock Repurchase Authorization: Track the remaining $41.3 million (approx. 1.7 million shares) authorized for repurchase and the company's commitment to returning capital to shareholders.